SCHEMBL6314872

SCHEMBL6314872

NC(=O)c1c(-c2ccncc2)noc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
MAPK14 Q16539 2/20 0.49
LMNA P02545 1/20 0.48
RAB9A P51151 1/20 0.48
SRC P12931 2/20 0.47
KDR P35968 2/20 0.47
BRAF P15056 1/20 0.47
MLYCD O95822 1/20 0.45
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA4 P22748 4/20 0.41
CA7 P43166 4/20 0.41
MAP2K3 P46734 2/20 0.41
CDC7 O00311 2/20 0.40
DBF4 Q9UBU7 2/20 0.40
CCNE1 P24864 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314989 0.87 MAPK14 (0.49) KMT2AMEN1GAAMAPK14LMNA
SCHEMBL6315391 0.81 IKBKB (0.51) KMT2AMEN1GAALMNARAB9A
SCHEMBL6318683 0.80 IKBKB (0.50) KMT2AMEN1GAALMNARAB9A
SCHEMBL6316560 0.75 SMN1; SMN2 (0.59) KMT2AGAARAB9AMAPK1SMN1; SMN2
SCHEMBL6620565 0.75 LMNA (0.47) KMT2AMEN1GAAMAPK14LMNA
SCHEMBL6316604 0.74 ALDH1A1 (0.57) GAAMAPK1SMN1; SMN2CA1CA2
SCHEMBL27610083 0.74 ALDH1A1 (0.51) KMT2AMAPK14LMNARAB9AMAPK1
SCHEMBL6317594 0.74 CA1 (0.48) KMT2AMEN1GAALMNARAB9A
SCHEMBL27591476 0.74 MAPK14 (0.50) KMT2AMEN1GAAMAPK14RAB9A
SCHEMBL6323338 0.73 ALDH1A1 (0.50) KMT2AMEN1GAAMAPK14RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KMT2A 1089/4885MEN1 2789/4885GAA 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.